Elevidys’ expanded scope of application includes Duchenne muscular dystrophy patients aged 4 years and older, regardless of ambulatory status.
FDA Expands Approval of Sarepta Therapeutics’ Erevidys for Treatment of Duchenne Muscular Dystrophy
Leave a comment
